By Nancy Lapid (Reuters) - Novel triple-drug therapies are showing promise for patients with various kinds of leukemia, ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

Hopes of a bright new future in stroke risk management in AF were dashed when asundexian failed against apixaban in the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/91.IM06wodO.js ...

This was the stock's third consecutive day of losses.

Savvy plaintiffs-side attorneys are leveraging this split to avoid bringing their FLSA collective action where the employer ...

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with ...

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

Accent Therapeutics appoints Serena Silver as chief scientific officer as it advances Phase I/II ATX-559 trials for advanced ...